F

For booking details & registration fees please refer to the last page or visit: http://www.proteins-congress.com/marketing

Protein Purification Custom Protein Production Screening Technologies

Custom Antibody Production Antibody Purification

Antibody Design

Recombinant Proteins Monoclonal Antibodies Imaging Tools

High Throughput Platforms Immunoassay Kits Protein Library Design

Discover New Solutions Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Protein Science Protein Engineering Protein Characterisation

Protein Purification Protein Biochemistry Antibody Discovery

Antibody Optimisation Antibody Technologies Antibody Engineering

Biologics Screening Therapeutic Discovery Alternative Scaffolds

Benefits to Attending

Hear from and meet with the key innovators in proteins & antibodies.

Attendees include: Vice President, AstraZeneca; Vice President, UCB, Vice President, MedImmune

Discover collaborative solutions to protein engineering, designs and

selection. Our highly established event will bring together key opinion

leaders to discuss novel approaches to protein engineering, improving

protein half-life extension and updates in antibody structure and dynamics

Discuss the latest innovations in protein & antibody therapeutics.

Protein therapeutics case studies will include the areas of oncology,

cancer & viral diseases. Updates in antibody discovery and optimisation

will also be addressed

Examine advancements in protein analytics. Hear updates in protein

characterisation, structure and novel approaches to express proteins

utilising cell-based and bacterial systems

Unparalleled networking opportunities. The two-day congress offers

dedicated networking breaks creating an interactive platform for scientific

discussions and 1-1 meetings. The exhibition hall and poster presentation

spaces offer a relaxed and professional environment for discussion

A high quality programme devised with the help of our esteemed

advisory board. Presentations will cover key updates in protein science,

protein stability, alternative scaffolds as well as evaluating different protein

expression technologies

Featuring two new streams on protein & antibody biotherapeutics

Co-located with the highly anticipated 4th Annual Peptides Congress

2017 Speakers Include…

Bohong Zhang Lorenz Mayr Orla Cunningham Shire Pharmaceuticals Inc. AstraZeneca Pfizer Inc.

Meet Senior Decision Makers

400 senior attendees from leading pharmaceutical, biopharmaceutical, academics, CRO and solution provider companies will be attending. Meet Senior VPs, Directors, & Managers with the following job titles:

Proteins & Antibodies Congress Day 1 Stream 1 – Advances in Protein Engineering, Design & Selection

Novel approaches to protein engineering

Improving protein half-life extension, potency & selectivity

Developability of proteins through innovative engineering and design approaches

Contribution of advanced computational design and development of biocatalysts to protein engineering

Day 2 Stream 1 – Antibody Development, Engineering & Design

Updates in antibody structure and dynamics

Generation of antibody diversity

Antibody effector mechanisms

Improvements in antibody drug conjugates

Featured Streams on Protein & Antibody Biotherapeutics Day 1 Stream 2 – Antibody Biotherapeutics

Accelerating antibody discovery & optimisation: o Bispecific and multivalent antibodies o Monoclonal antibodies o Antibody drug conjugates

Cutting edge technologies for antibody discovery

T cell redirection strategies

Targeting immune checkpoints

Antibody combinations & bispecifics

Day 2 Stream 3 – Protein & Antibody Biotherapeutics

Case studies from the areas of: o Oncology diseases o Infectious diseases o Viral diseases o Neurodegenerative diseases o Cardiovascular and metabolic diseases

Overcoming immunogenicity and aggregation hurdles

Improving protein stability

Alternative scaffolds: challenges & opportunities

Updates in fusion proteins

Day 2 Stream 2 – Cloning, Expression, Purification & Analytics

New strategies to improve protein expression

Updates in protein purification

Updates in crystallisation technologies

Recent advancements in protein characterisation

Detection of antibodies by LC/MS

Evaluating different protein expression technologies

Updates in protein expression utilising cell-based and bacterial systems

Complimentary Webinar:

Advances In Protein & Antibody Biotherapeutics, 7th February 2017

Improved Non-Invasive Routes Of Administration Of Peptides, 16th February 2017

Register for free - email marketing@oxfordglobal.co.uk

For more information please contact marketing@oxfordglobal.co.uk

If you’re on Twitter, make sure to follow us @ProteinCongress and join the Congress conversation using #Proteins2017

2017 Confirmed Speakers Include:

Lorenz Mayr, Vice President, Biological Reagents & Assay Development, AstraZeneca

Rene Hoet, Vice President, Global Biologics, Bayer

Rakesh Dixit, Vice President, Research & Development, MedImmune

Alastair Lawson, Vice President, Structural Biology, UCB

Kristen Picha, Scientific Director, Janssen BioTherapeutics, Janssen R&D

Benno Rattel. Executive Director, Amgen

Kalpit Vora, Director, Infectious Disease and Vaccine Based Research, Merck & Co., Inc.

Andrew Goodearl, Director, AbbVie

Rudolf de Wildt, Director, Biopharm R&D & Head of Lead Discovery, GlaxoSmithKline

Yan Wu, Director and Principal Scientist, Genentech

Alistair Henry, Senior Director, UCB Celltech

Bohong Zhang, Director, Head of Protein Production, Discovery Therapeutics, Shire Pharmaceuticals Inc.

Orla Cunningham, Director, Biomedicine Design, Pfizer, Inc.

Daniel Lightwood, Director, Antibody Discovery, UCB

W. Blaine Stine, Associate Director, Discovery Biologics, AbbVie

Ercole Rao, Head Engineered Protein Therapeutics, Sanofi

Vivian Lindo, Associate Director, Product Characterisation, MedImmune

Ralf Schumacher, Global Head Bioprocess and Pharmaceuticals Development, Boehringer Ingelheim

Thorsten Lorenz, Group Head, Developability Assessment Biologics, Novartis

Alexey Rak, Head of Bio Structure and Biophysics, Sanofi

Thomas Jostock, Group Head, Cell Line Development, Novartis

Donmienne Leung, Principal Research Scientist, Eli Lilly

Dasa Lipovsek, Senior Principal Scientist, Bristol-Myers Squibb

Matthew Beard, Senior Principal Scientist, Ipsen

Antonietta Impagliazzo, Principal Scientist, Janssen

James Hunt, Team Leader, AstraZeneca

Darko Skegro, Senior Team Leader, Novartis

Tilman Schlothauer, Group Leader, Roche Pharmaceuticals

Shirley Peters, Senior Scientist, Antibody and Protein Engineering and Design, UCB

Whitney Shatz, Senior Research Scientist, Genentech

Caroline Colley, Senior Scientist, Antibody Discovery and Protein Engineering, MedImmune

T. Noelle Lombana, Senior Scientific Researcher in Antibody Engineering, Genentech

William G. Romanow, Senior Associate Scientist, Protein Technologies, Amgen, Inc.

Lothar Germeroth, Senior Vice President and Managing Director, Juno Therapeutics

Antonin de Fougerolles, Chief Scientific Officer, Ablynx

Veronique Lecault, Co-founder, AbCellera

Jens Frauenfeld, Chief Executive Officer, Salipro Biotech AB

Thomas Sandal, Vice President R&D, Crescendo Biologics

Joachim Feldwisch, Director Preclinical Development, Affibody AB

Mikael Mattsson, Director Antibody Discovery, BioInvent International AB

James Errey, Associate Director, Biomolecular Structure, Heptares Therapeutics

Benoit Combaluzier, Head of Antibody Discovery, Neurimmune Therapeutics

Pierre Moretti, Head of Cell Line Development, Glenmark Pharmaceuticals SA

Sven Berger, Head of Mammlian Expression, Pieris Pharmaceuticals

Alan L. Epstein, Professor of Pathology, USC Keck School of Medicine

Naomi Chayen, Professor of Biomedical Sciences, Imperial College London

Kerstin Otte, Professor, University of Applied Sciences

Yoram Reiter, Professor, Israel Institute of Technology

Paul Dalby, Professor of Biochemical Engineering and Biotechnology, University College London

Manfred Konrad, Research Director, Enzyme Biochemistry Laboratory, Max Planck Institute for Biophysical Chemistry

For more information please contact marketing@oxfordglobal.co.uk

2017 Confirmed Sponsors Include:

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day One – 24th April 2017

07.30 – 08.05 Registration

08.05 – 08.10 Oxford Global’s Welcome Address

08.10 – 08.15 Chairperson’s Opening Address

08.15 – 09.00 Co-located Event Keynote Address: The Human Secretome Project – A Combination Of Phenotypic And Target-based Drug Discovery Strategies Use of secreted and transmembrane proteins as drug targets for antibodies and small molecules

Generation of the human secretome, a set of 6400 different human proteins in their active state

Phenotypic and target-based screening of the ‘AZ/KTH secretome library’ in biological effect assays

Lorenz Mayr, Vice President, Biological Reagents & Assay Development, AstraZeneca

Advances In Protein Engineering, Design & Selection Antibody Biotherapeutics

09.00 – 09.30 Stream Keynote Address: Targeting Bi-specific Biologics To Disease Tissues The development of clinically validated bi-specific biologics platforms such as dual

variable domain immunoglobulins (DVD-Igs) has permitted the exploration of tissue specific and disease tissue specific targeting of biologics.

We will describe preclinical examples of tissue targeting in normal and disease in vivo models as part of a new generation of locally acting “regio-specific” biologics therapies

Andrew Goodearl, Director, AbbVie

Antibody Engineering To Support Therapeutic Areas

Yan Wu, Director and Principal Scientist, Genentech

09.30 – 10.00 Solution Provider Presentation – RESERVED

Malvern Instruments

Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk

10.00 – 11.20 Morning Coffee & Refreshments, Poster Presentation Sessions, One to One Meetings x3

11.20 – 11.50 Translating Discovery Knowledge Into Process Design Ralf Schumacher, Global Head Bioprocess and Pharmaceuticals Development, Boehringer Ingelheim

Efficient Mining Of The B Cell Repertoire – Finding Rare Antibodies With Desirable Characteristics UCB’s core antibody discovery technology enables extremely efficient interrogation of the natural

antibody repertoire

The platform combines high throughput B cell culture screening and a proprietary technique called the “fluorescent foci method” to identify and isolate single, antigen-specific, IgG-secreting B cells

We will describe the technology and provide examples of how we have applied the platform to a range of antibody discovery projects

Daniel Lightwood, Director, Antibody Discovery, UCB

11.50 – 12.20 Engineering A Hexameric Fc For Altered Immune Effector Function Introduction to the design and generation of the multimeric Fc

Use of a “design of experiment” approach to design molecules based on differential FcgR engagement observed for IgG1 or IgG4

Analysis of molecules including FcgR binding and functional cell assays

Shirley Peters, Senior Scientist, Antibody and Protein Engineering and Design, UCB

A Bi-Specific Centyrin Targeting EGFR And c-Met Inhibits Cellular Signaling Through Avidity

Kristen Picha, Scientific Director, Janssen BioTherapeutics, Janssen R&D

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day One – 24th April 2017

12.20 – 12.50 Solution Provider Presentation

For sponsorship opportunities please contact

sponsorship@oxfordglobal.co.uk

Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk

12.50 – 13.50 Lunch

13.50 – 14.20 Developability Of Biologics – The Novartis Perspective Thorsten Lorenz, Group Head, Developability Assessment Biologics, Novartis

BiTE® Antibody Constructs For Cancer Therapy Bispecific T-cell engagers

BiTE® antibody constructs

Blincyto®

Nonclinical assessment

Translation into the clinic

Benno Rattel, Executive Director, Amgen

14.20 – 14.50 The Bispecific Challenge: A Novel And Efficient Platform For The Expression Of Bispecific IgGs

Darko Skegro, Senior Team Leader, Novartis

Progress And Challenges With The Isolation And Optimization Of Antibodies – The Good, Bad And Ugly This talk will discuss GSKs progress with the isolation of antibodies for a number of projects using GSKs in vitro and in vivo Antibody platforms.

Overview of GSKs Antibody discovery processes

Case studies: Some innovative design and selection approaches will be discussed, including isolating antibodies against complex targets such as GPCRs

Rudolf de Wildt, Director, Biopharm R&D & Head of Lead Discovery, GlaxoSmithKline

14.50 – 15.20 Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk

Solution Provider Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk

15.20 – 16.20 Afternoon Refreshments, Poster Presentation Sessions, One to One Meetings x2

16.20 – 16.50 Predicting Long-term Stability And Aggregation Propensity Of Proteins Using Novel Biophysical Tools Biophysical approaches are routinely used to assess biologics activities, stability and quality. Modern drug discovery operations require characterization of biomolecular interactions to be both time- and cost-effective as well as to be highly precise and reproducible. Here we report applications of two novel methods, nano-Differential Scanning Fluorimetry (nanoDSF) and MicroScale Thermophoresis (MST), that we are applying in our biologics discovery and characterization operations. The examples of the demonstrated effectiveness of the nanoDSF and MST will be presented and discussed.

Alexey Rak, Head of Bio Structure and Biophysics, Sanofi

Advances In Bispecific Antibody Formats: Modelling A New Cross-over Design To Address Novel Biology Modelling and engineering of a new bispecific antibody format

modulating half-life, valency, and potency, engineering stability

T-cell retargeting, neutralization of targets

Ercole Rao, Head Engineered Protein Therapeutics, Sanofi

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day One – 24th April 2017

16.50 – 17.20 Protein Stabilisation Through Formulation And Protein Engineering, Guided

By Computational Methods Computational design and testing of variants of therapeutic proteins with improved

stability

Prediction of formulation excipients for protein stabilization

Paul Dalby, Professor of Biochemical Engineering and Biotechnology, University College London

Antibody Biotherapeutics – Ocular Applications Whitney Shatz, Senior Scientific Researcher, Genentech

17.20 – 17.50 The Salipro System For Stabilization Of Membrane Proteins Salipro® nanoparticles allow for the reconstitution of membrane proteins in a lipid

environment: GPCRs, Transporters, Channels, Receptors

Nanoparticles adjust to size of membrane proteins, incorporation of monomers as well as large homo/hetero-oligomeric complexes

Technology allows to work with membrane proteins in detergent-free buffer systems

Salipro-Membrane-Proteins enable high-resolution cryoEM, structural studies, drug screenings and generation of antibodies

Jens Frauenfeld, Chief Executive Officer, Salipro Biotech AB

Utilising Nanobodies For Immunotherapy Advances in multivalent and multi-specific Nanobodies for immune-oncology

Case study: Using multi-specific Nanobodies to generate the next generation T cell recruiter platform

Case study: Improving agonist activity using a multivalent GITR Nanobody

Antonin de Fougerolles, Chief Scientific Officer, Ablynx

17.50 – 18.20 Discovery Of Therapeutic Antibodies From Natural Immune Repertoires Using A Single-cell, High-throughput Platform Veronique Lecault, Co-founder, AbCellera

18.20 – 18.50 Juno´s Cell Handling Platform For Efficient Production Of Gene-modified T-Cells Car T cells have shown very promising clinical efficacy in patients with haematological malignancies. Driven by the clinical benefits a substantial future demand has to be satisfied by products with very complex production procedures. Standardization, productivity, and scalability are prerequisites to generate high-quality cell products in sufficient quantities. Juno is developing a cell handling platform which addresses the main questions in car T cell production to meet future demands. New Juno technologies such as T-Catch, Expamers and Streptamers will be discussed in the context of an efficient production platform.

Lothar Germeroth, Senior Vice President and Managing Director, Juno Therapeutics

18.50 – 19.20 Engineering An Affibody® Fusion Protein Trap Towards Therapeutic Blocking Of IL-17 In <an Psoriasis is an IL-17 driven disease

An Affibody® based 18.6 kDa ligand trap was engineered to block IL-17A with femtomolar affinity

The trivalent bispecific fusion protein blocks IL-17 with unparalleled affinity and displays long plasma half-life as shown in man

Early development and data from Phase I/II will be presented

Joachim Feldwisch, Director Preclinical Development, Affibody AB

19.20 – 19.50 Broadly Neutralizing Human Monoclonal JC Polyomavirus VP1-Specific Antibodies For The Treatment Of Progressive Multifocal Leukoencephalopathy

Generation of human monoclonal antibodies against JCPyV using the Neurimmune RTMTM technology

Human JCPyV-specific monoclonal antibodies inhibit viral infection in vitro and cross-react against the most common PML-associated mutants

Promising drug candidates for the development of a treatment of PML, a lethal brain disease with a very high unmet medical need

Benoit Combaluzier, Head of Antibody Discovery, Neurimmune Therapeutics

19.50 Networking Drinks End of Day One

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day Two – 25th April 2017

Conference Room:

Stream Chair:

08.30 -09.00 Keynote Address: Next Generation Of Antibody Drug Conjugates: A Step Forward To Magic Anti-Cancer Bullets Advances in maximizing TI of ADCs

Next generation of cytotoxic warheads

Advances in bispecific ADCs

Translational approaches to ADC Development

Rakesh Dixit, Vice President, Research & Development, MedImmune

Antibody Development, Engineering & Design Cloning, Expression, Purification & Analytics Protein & Antibody Biotherapeutics

09.00 – 09.30 New Aspects Of Antibody Therapeutics Both From A Discovery As Well As Optimization Prospective

Rene Hoet, Vice President, Global Biologics, Bayer

Cloning, Expression, Purification & Analytics Of Recombinant Proteins For Drug Discovery Multiple approaches to improve protein expression

Develop affinity resin for protein purification

Cell line engineering to improve glycosylation of recombinant proteins

Bohong Zhang, Director, Head of Protein Production, Discovery Therapeutics, Shire Pharmaceuticals Inc.

Stream Keynote Address: Recombinant Botulinum Neurotoxins As New Biotherapeutics Botulinum neurotoxins are successful biotherapeutics for

the treatment of several diseases

Recombinant technology provides opportunity to create new toxin based-products to treat diseases in the areas of neurology and beyond

Here we present a case study: creation and characterisation of a recombinant neurotoxin

Matthew Beard, Senior Principal Scientist, Ipsen Bioinnovation

09.30 – 10.00 Use Of Synthetic Antibody Libraries For Efficient Isolation Of Conventional And Bispecific Human mAbs Efficient lead generation using llamdA, a humanized single

domain antibody library

A novel synthetic human antibody Fab library, 4DFab

Combining both solutions enables licensees to create a variety of bispecific biopharmaceutical formats

Guy Hermans, CSO, Isogenica

Antibody Engineering Meets Machine Learning Machine learning provides unambiguous pattern matching

of sequence-function correlation in megadimensional protein space

Gene synthesis allows for efficient and exact creation of systematically varied antibodies designed to explore the relevant space

Applying machine learning on the antibody-set provides detailed information on the relative weight contribution of each amino acid substitution and its synergistic constraint

Modeling of the predicted vs measured antibody activities provides a detailed map of how to engineer the antibodies for improved functionality

Claes Gustafsson, CCO & Co-Founder, DNA 2.0

Solution Provider Presentation

For sponsorship opportunities please contact

sponsorship@oxfordglobal.co.uk

10.00 – 11.00 Morning Coffee & Refreshments, Poster Presentation Sessions, One to One Meetings x2

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day Two – 25th April 2017

11.00 – 11.30 CDR-restricted Engineering For Antibody

Optimization & Humanization Restricting mutation to naturally diverse CDRs allows

maintenance of 100% germline frameworks

CDRs can be manipulated to enable affinity, stability, specificity & solubility optimization

CDRs can be extensively germlined for ultra-humanization whilst maintaining optimal affinity

A number of case studies will be used to highlight these concepts

Orla Cunningham, Director, Biomedicine Design, Pfizer, Inc.

Novel Protein Characterisation Formats And Methods

Vivian Lindo, Associate Director, Product Characterisation, MedImmune

Adnectins Designed For Therapeutic Applications Adnectins are a family of engineered target-binding proteins

based on the 10th human fibronectin type III domain (10Fn3)

The small size (10 kDa) of Adnectins leads to their fast elimination from the bloodstream

The simple structure and biophysical robustness of Adnectins allows their pharmacokinetics to be modified by chemical conjugation or genetic fusion to longer-lived molecules

This presentation will focus on matching Adnectin format and half-life to the specific application

Dasa Lipovsek, Senior Principal Scientist, Bristol-Myers Squibb

11.30 – 12.00 Solution Provider Presentation

Solution Provider Presentation

For sponsorship opportunities please contact

sponsorship@oxfordglobal.co.uk

Solution Provider Presentation

For sponsorship opportunities please contact

sponsorship@oxfordglobal.co.uk

12.00 – 12.30 Sampling Human Responses To Design Vaccines Kalpit Vora, Director, Infectious Disease and Vaccine Based Research, Merck & Co., Inc.

Detecting Antibodies By Liquid Chromatography–Mass Spectrometry

Alistair Henry, Senior Director, UCB Celltech

Developing Protein Therapeutics For Alzheimer’s Disease

Antonietta Impagliazzo, Principal Scientist, Janssen

12.30 – 13.30 Lunch

13.30 – 14.00 Antibodies As Tools In Small Molecule Drug Discovery Therapeutic antibodies have pioneered the modulation of

protein-protein interactions in the clinic

Antibodies are now being used as tools to define specific conformations of target proteins, providing new opportunities for intervention, and enabling the discovery of small molecules which modulate protein-protein interactions

Alastair Lawson, Vice President, Structural Biology, UCB

Combined Vector & Cell Engineering Strategies To Improve The Expression Of Biotherapeutics Thomas Jostock, Group Head, Cell Line Development, Novartis

Updates In The Discovery Of Therapeutic Antibodies Using Phenotypic Screening Mikael Mattsson, Director Antibody Discovery, BioInvent International AB

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day Two – 25th April 2017

14.00 – 14.30 The Story Of ABT-122 And How AbbVie Leveraged An

Antibody-based Platform To Successfully Develop The First Bispecific DVD-Ig To Enter Clinical Development

W. Blaine Stine, Associate Director, Discovery Biologics, AbbVie

Recent Developments In Antibody Validation

James Hunt, Team Leader, AstraZeneca

Bioprocess Development For First-in-class Bispecific Anticalin-antibody Fusion: Fast, Robust And Efficient General descriptions of Anticalins and Anticalin fusion

proteins

Outline of the PRS-343 molecule and its biochemical characteristics

Discussion of the challenges in bispecific process development and advantages of Anticalin fusion proteins

Sven Berger, Head of Mammlian Expression, Pieris Pharmaceuticals

14.30 – 15.00 Eli Lilly Case Study On How They Resolved AN Engineering Problem For Bispecific Antibodies Donmienne Leung, Principal Research Scientist, Eli Lilly

Optimizing Antibody Expression By Using Natural Framework Diversity And Host Engineering In A Live Bacterial Antibody Display System Insights into a novel Bacterial Display system using full-

length formats for antibody and antigen in a live cell setting

Ways to improve expression and stability of antibodies in vitro by mimicking the natural antibody selection process, which translates to a mammalian host

Ways to improve antibody expression in host expression strains

T. Noelle Lombana, Senior Scientific Researcher in Antibody Engineering, Genentech

A New Molecule Redirecting T-cells Pierre Moretti, Head of Cell Line Development, Glenmark Pharmaceuticals SA

15.00 – 15.30 Afternoon Refreshments, Poster Presentation Sessions

15.30 – 16.00

Discovering Antibodies To A Moving Target In response to infections and irritants, the respiratory epithelium releases the alarmin IL-33 to elicit a rapid immune response. We have recently shown that IL-33 can form intra-chain disulphide bonds resulting in large conformational changes that disrupt the binding of IL-33 to its receptor, ST2. Here we will describe how, through innovative use of mutant forms of IL-33 in antibody phage display selections and appropriate design of screening campaigns, a highly potent inhibitory mAb to IL-33 was identified. This case study is testament to how a fundamental understanding of target structure and biology is key to the identification of potential therapeutic drug candidates.

Caroline Colley, Senior Scientist, Antibody Discovery and Protein Engineering, MedImmune

Baculovirus Expression Systems In Support Of Structure Studies For Drug Discovery Case studies in producing protein for several challenging

crystallography targets

Production of secreted protein, management of glycosylation states and prevention of lysis

The use of baculovirus as an expression vector system for mammalian cells

William G. Romanow, Senior Associate Scientist, Protein Technologies, Amgen, Inc.

Novel Fusion Proteins For The Immunotherapy Of Cancer

Alan L. Epstein, Professor of Pathology, USC Keck School of Medicine

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day Two – 25th April 2017

16.00 – 16.30 Small Is Beautiful – Humabodies Drug Conjugates,

HDC’s A Real Alternative To ADC’s HDC demonstrate exceptionally fast tumour penetration

HDC facilitate low systemic exposure

Humabodies enable plug and play engineering allowing simple exploration of limitless format options

The versatility of the Humabody™ format enables creation of optimal HDC format and half-life with improved Therapeutic Index

Thomas Sandal, Vice President R&D, Crescendo Biologics

Analytical Fc Receptor Affinity Chromatography for Functional Characterization

Tilman Schlothauer, Group Leader, Roche Pharmaceuticals

Targeting The Intracellular Proteome For Developing Novel Immunotherapies For Cancer, Autoimmunity, And Inflammation

Yoram Reiter, Professor, Israel Institute of Technology

16.30 – 17.00 Purification And Biophysical Characterisation Of GPCR's

James Errey, Associate Director, Biomolecular Structure, Heptares Therapeutics

Improving Current Enzyme-based Therapy Of Acute Lymphoblastic Leukemia: Molecular Engineering And Directed Evolution Of Human L-asparaginases The enzyme L-asparaginase (L-ASNase) is an approved

drug for the treatment of acute lymphoblastic leukemia (ALL). Depletion of the free amino acid L-asparagine (L-Asn) from the blood stream selectively blocks protein biosynthesis and induces apoptosis of these leukemic cells

The two FDA-approved enzymes are of bacterial origin; they display innocuous side effects mainly attributed to immunogenicity and hypersensitivity reactions

This talk highlights novel approaches for the design and molecular evolution of human L-ASNases that could replace clinically approved bacterial enzymes

We present fabrication of biocompatible nanomaterials serving as microcarriers for protein molecules

Manfred Konrad, Research Director, Enzyme Biochemistry Laboratory, Max Planck Institute for Biophysical Chemistry

17.00 – 17.30 Enhancing The Success Of Crystallising Proteins Related To Therapy I will present a variety of practical ways to increase the chances of success by showing

The ideas and inspiration

The rationale

Examples of successful results

Naomi Chayen, Professor of Biomedical Sciences, Imperial College London

For more information please contact marketing@oxfordglobal.co.uk

10th Annual Proteins & Antibodies Congress

Day Two – 25th April 2017

17.30 – 18.00 Tiny But Mighty – Effective MicroRNAs For Next Generation Cell Engineering

MicroRNAs constitute an important class of non-coding RNAs. Individual miRNAs control entire bioprocess relevant cellular pathways and thus receive growing attention in biotechnology. A high-content miRNA screening in CHO cells discovered hundreds of miRNAs to substantially improve bioproduction. Our comprehensive miRNA research led to the generation of a ‘miRNA target catalog’ providing an avenue for next-generation CHO cell engineering.

Kerstin Otte, Professor, University of Applied Sciences

18.00 End of Conference

10th Annual Proteins & Antibodies Congress Conference: 24-25 April 2017 Novotel London West, UK

www.proteins-congress.com

HOW TO REGISTER: FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: marketing@oxfordglobal.co.uk

Please complete fully and clearly. Please photocopy for additional delegates Title:_____Forename:_______________Surname:________________ Job Title:_________________________________________________ Company/Organisation:_____________________________________ Email:___________________________________________________ Address:_________________________________________________ ________________________________________________________ Postcode: ____________________ Country: ___________________ Direct Telephone ________________ Direct Fax: ________________ Mobile: ________________________ Switchboard: _____________ Signature: ______________________ Date: _____________________

Number of delegates:

Industry del(s) Academic dels(s) Vendor dels(s) Special Offer: 3 for 2

Offer is only valid on the congress and for those registering at Industry or Academic rates

CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number:

Valid from: / Expiry Date: /

Security code:

Cardholders name: _______________________________________

Signature: ______________________________ Date: ___________

PLEASE INVOICE ME:

Invoice Address (if different from above)_______________________

*Please note there is a £50 plus VAT handling charge for payment via invoice *All card payments will be subject to a 3% bank charge or 4% AMEX charge

Registration Fees

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate: Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 + VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to pay-ments settled online. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility. Poster Presentations Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size. Cancellation and Curtailment Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation. More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee/ 25% refund Less than 3 months prior to the event Full cancellation fee / No refund Data Protection The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/her personal and company information on the terms set out herein. Miscellaneous This Agreement may not be transferred or assigned by either the Delegate or the Delegate’s Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded.

I agree to the above Terms and Conditions

How to Pay (choose one of the following payment options)

I would like to attend: (Please tick as appropriate) Industry Delegates (Biopharma, Pharma or Biotech Companies)

Congress £799 plus VAT

1 day pass £499 plus VAT

Day 1 Day 2

Academic Delegates

Congress £499 plus VAT 1 day pass £299 plus VAT Day 1 Day 2

Vendor Delegates (CROs, Consultants, Technology and Service Providers)

Congress Only £1350 plus VAT 1 day pass £799 plus VAT Day 1 Day 2

Poster Presentation £250 plus VAT

PROMOTIONAL LITERATURE DISTRIBUTION

Distribution of your company’s promotional literature to all conference attendees £999 plus VAT

Documentation

I cannot attend but would like to purchase access to the following:

Access to the online conference presentations £499 plus VAT Conference presentations - paper copy £499 plus VAT

VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk

Terms & Conditions of Booking

Delegate Details